Evaxion Biotech (EVAX)

• Market cap: $5.25M
• 1 day: -1.42%
• 5 days: -4.82%
• 1 month: -40.74%
• 3 months: -69.87%
• 6 months: -66.74%
• Year to date: -87.74%
• 1 year: -87.31%
• 5 years: -99.10%
• 10 years: -99.10%

About: Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Employees: 49

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more funds holding

Funds holding: 6 [Q2] → 8 (+2) [Q3]

30% more capital invested

Capital invested by funds: $1.31M [Q2] → $1.71M (+$392K) [Q3]

0.11% more ownership

Funds ownership: 0.87% [Q2] → 0.98% (+0.11%) [Q3]

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $14 1,465% upside
• Avg. target: $14 1,465% upside
• High target: $14 1,465% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 27% 1-year accuracy 46 / 173 met price target

1,465% upside $14

Buy Reiterated

1 Nov 2024